Eli Lilly and Company (NYSE:LLY) Given Consensus Recommendation of "Moderate Buy" by Analysts

Eli Lilly and Company (NYSE:LLY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nineteen research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $1,017.67.

Several research firms have weighed in on LLY. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Truist Financial increased their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a report on Monday, February 3rd. Citigroup reduced their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. StockNews.com raised shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 0.13% of the company's stock.

Institutional Trading of Eli Lilly and Company

Several institutional investors have recently made changes to their positions in LLY. Regent Peak Wealth Advisors LLC boosted its holdings in Eli Lilly and Company by 4.1% during the first quarter. Regent Peak Wealth Advisors LLC now owns 2,666 shares of the company's stock valued at $2,202,000 after purchasing an additional 104 shares in the last quarter. TB Alternative Assets Ltd. bought a new stake in Eli Lilly and Company in the first quarter valued at $487,000. Sivia Capital Partners LLC increased its position in shares of Eli Lilly and Company by 13.4% during the 1st quarter. Sivia Capital Partners LLC now owns 2,092 shares of the company's stock worth $1,728,000 after purchasing an additional 248 shares in the last quarter. Perkins Coie Trust Co increased its holdings in shares of Eli Lilly and Company by 8.6% during the first quarter. Perkins Coie Trust Co now owns 6,571 shares of the company's stock worth $5,427,000 after buying an additional 521 shares in the last quarter. Finally, Joule Financial LLC raised its holdings in shares of Eli Lilly and Company by 8.3% in the first quarter. Joule Financial LLC now owns 312 shares of the company's stock valued at $258,000 after buying an additional 24 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of LLY traded up $11.45 during trading hours on Friday, hitting $743.86. 338,633 shares of the company were exchanged, compared to its average volume of 3,374,986. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company has a market capitalization of $705.30 billion, a PE ratio of 63.31, a PEG ratio of 1.40 and a beta of 0.51. The firm has a fifty day simple moving average of $837.05 and a 200-day simple moving average of $822.87. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.